Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rebus Holdings, Inc. (RBSH)
Westlake Village, CA, US
Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.07% | -99.98% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+51.6% ★ Q2'23: +98.0% (vs Q2'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'23: -3.5% (vs Q2'22)
-
Share dilution Biotechnology: -3.4%-99.6% ★ Q2'23: 0.0% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.47× Q2'23: 0.51× (vs Q2'22)
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Craig A. Dionne | 5.64M | 12.50% | 4.64M | 1.00M | 4.64M | — | IN | United States | 2016-02-16 | ↗ |
| 2 | Dr. Kihong Kwon | 4.03M | 11.80% | 3.74M | 281.1K | 3.74M | — | IN | United States | 2014-12-15 | ↗ |
| 3 | Russell Richerson | 3.64M | 10.30% | 3.64M | — | 3.64M | — | IN | United States | 2014-12-15 | ↗ |
| 4 | Alpha Capital Anstalt | 2.36M | 7.21% | 2.36M | — | 2.36M | — | CO | Liechtenstein | 2014-12-19 | ↗ |
| 5 | Sabby Healthcare Master Fund, Ltd. | 1.43M | 3.85% | — | 1.43M | — | 1.43M | CO | Cayman Islands | 2015-07-22 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
| Filing date | Form type | Filing |
|---|---|---|
| 2020-10-15 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John T. Isaacs | Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor | — | — |
| Raul Silvestre | Chief Executive Officer, Chief Financial Officer, President, Principal Accounting Officer & Director | — | male |
| Samuel R. Denmeade | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RBSH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
